fluphenazine depot has been researched along with Basal Ganglia Diseases in 14 studies
fluphenazine decanoate : The prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluphenazine was significantly effective in treating symptoms such as emotional withdrawal, blunted affect, suspiciousness, thought disturbances, but not hallucinations." | 5.28 | Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. ( Altamura, AC; Girardi, T; Mauri, MC; Panetta, B, 1990) |
| "This study evaluated the feasibility and impact of gradually reducing relatively high doses of fluphenazine decanoate by one-half for chronically impaired, poor inner-city patients with schizophrenia." | 5.07 | A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. ( Egan, GJ; Gloersen, BA; Inderbitzin, LB; Lewine, RR; Scheller-Gilkey, G; Swofford, CD; Vidanagama, BP; Waternaux, C, 1994) |
| "The risk of adverse side effects of neuroleptic agents must be considered carefully in the treatment of acute and long-term psychotic states." | 3.75 | Antipsychotic drug side effects: their relationship to dose. ( Kane, JM, 1985) |
| "A patient with chronic schizophrenia treated with fluphenazine developed neuroleptic malignant syndrome, characterized by fever, obtundation, rigidity, and tremulousness." | 3.66 | Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. ( Adler, S; Coyle, J; Granato, JE; Karim, AH; Krumholz, A; Ringel, A; Stern, BJ, 1983) |
| " It is suggested that additional studies, carefully designed, on dosage and plasma levels could help in achieving the lowest possible therapeutic dosage and thus in minimizing side effects." | 2.37 | Blood levels of neuroleptics: state of the art. ( Simpson, GM; Yadalam, K, 1985) |
| "Fluphenazine was significantly effective in treating symptoms such as emotional withdrawal, blunted affect, suspiciousness, thought disturbances, but not hallucinations." | 1.28 | Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. ( Altamura, AC; Girardi, T; Mauri, MC; Panetta, B, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (57.14) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giugni, EA | 1 |
| Boddy, RS | 1 |
| Limet, NG | 1 |
| Chouinard, G | 1 |
| Annable, L | 1 |
| Ross-Chouinard, A | 1 |
| Kane, JM | 2 |
| Woerner, M | 1 |
| Weinhold, P | 1 |
| Wegner, J | 1 |
| Kinon, B | 1 |
| Dencker, SJ | 1 |
| Glazer, WM | 1 |
| Granato, JE | 1 |
| Stern, BJ | 1 |
| Ringel, A | 1 |
| Karim, AH | 1 |
| Krumholz, A | 1 |
| Coyle, J | 1 |
| Adler, S | 1 |
| Johnson, AE | 1 |
| Liminga, U | 1 |
| Lidén, A | 1 |
| Lindefors, N | 1 |
| Gunne, LM | 1 |
| Wiesel, FA | 1 |
| Hogarty, GE | 1 |
| McEvoy, JP | 1 |
| Ulrich, RF | 1 |
| DiBarry, AL | 1 |
| Bartone, P | 1 |
| Cooley, S | 1 |
| Hammill, K | 1 |
| Carter, M | 1 |
| Munetz, MR | 1 |
| Perel, J | 1 |
| Harasko-van der Meer, C | 1 |
| Brücke, T | 1 |
| Wenger, S | 1 |
| Fischer, P | 1 |
| Deecke, L | 1 |
| Podreka, I | 1 |
| Inderbitzin, LB | 1 |
| Lewine, RR | 1 |
| Scheller-Gilkey, G | 1 |
| Swofford, CD | 1 |
| Egan, GJ | 1 |
| Gloersen, BA | 1 |
| Vidanagama, BP | 1 |
| Waternaux, C | 1 |
| Altamura, AC | 1 |
| Mauri, MC | 1 |
| Girardi, T | 1 |
| Panetta, B | 1 |
| Simpson, GM | 1 |
| Yadalam, K | 1 |
| Sachdev, PS | 1 |
3 reviews available for fluphenazine depot and Basal Ganglia Diseases
| Article | Year |
|---|---|
Depot fluphenazine: risk/benefit ratio.
Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Fe | 1984 |
Antipsychotic drug side effects: their relationship to dose.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Respon | 1985 |
Blood levels of neuroleptics: state of the art.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Drug | 1985 |
5 trials available for fluphenazine depot and Basal Ganglia Diseases
| Article | Year |
|---|---|
Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Doub | 1982 |
Depot fluphenazine: risk/benefit ratio.
Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Fe | 1984 |
Pharmacotherapy of impaired affect in recovering schizophrenic patients.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Anxiety Disorders; Basal Ganglia Diseases; | 1995 |
A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Topics: Adult; Ambulatory Care; Basal Ganglia Diseases; Chronic Disease; Delayed-Action Preparations; Double | 1994 |
Antipsychotic drug side effects: their relationship to dose.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Respon | 1985 |
8 other studies available for fluphenazine depot and Basal Ganglia Diseases
| Article | Year |
|---|---|
Mis-deca-n identity?
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Dystonia; Fluphenazine; Humans; Male; Substance | 2007 |
A prospective study of tardive dyskinesia development: preliminary results.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Fem | 1982 |
The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
Topics: Administration, Oral; Antipsychotic Agents; Basal Ganglia Diseases; Biological Availability; Chronic | 1984 |
Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine.
Topics: Adult; Basal Ganglia Diseases; Bromocriptine; Dantrolene; Drug Therapy, Combination; Fluphenazine; H | 1983 |
Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Autoradiogr | 1994 |
Two cases of long term dopamine D2 receptor blockade after depot neuroleptics.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Dopamine D2 Receptor Anta | 1993 |
Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Topics: Aged; Basal Ganglia Diseases; Blood Pressure; Electrocardiography; Electroencephalography; Female; F | 1990 |
Lithium potentiation of neuroleptic-related extrapyramidal side effects.
Topics: Adult; Basal Ganglia Diseases; Bipolar Disorder; Drug Synergism; Drug Therapy, Combination; Female; | 1986 |